Duration of proton pump inhibitor abstinence before myocardial perfusion scintigraphy

Excerpt

The work of Singh et al1 takes further the concept that proton pump inhibitor (PPI) therapy is a significant cause of problematic artefacts in patients undergoing myocardial perfusion scinitigraphy using technetium methoxy-isobutyl-isonitrile (sestamibi), which we also found in our experience.2 Conducting their work as a randomized trial is a very commendable undertaking. We think it’s a very important work as this phenomenon often may result in misinterpretation of perfusion of inferior left ventricular segments. Consequently, appropriate subsequent cardiac catheterisation procedures may be deemed unnecessary. The whole saga is common to departments and practices everywhere. …